News
April 3, 2023
EIP Pharma Announces Presentation of Neuroimaging Data Exhibiting Potential Effects of Neflamapimod on Cholinergic Structure and Function at AD/PD™ 2023
Structural and functional brain MRI of patients before and after neflamapimod treatment shows increased NbM volume and increased functional dynamic connectivity between NbM and deep grey matter BOSTON, MA – April 3, 2023 – EIP Pharma Inc., a clinical stage company focused on developing treatments for neurodegenerative diseases, today announced the oral presentation by academic […]
Read MoreMarch 30, 2023
EIP Pharma and Diffusion Pharmaceuticals Announce Merger Agreement to Create Leading CNS-focused Company Treating Neurodegenerative Diseases
Combined company will pursue late-stage clinical development of oral neflamapimod for the treatment of dementia with Lewy bodies EIP Pharma to initiate in 2Q 2023 a Phase 2b clinical study, funded in part by a $21 million grant from the National Institute of Aging Combined company expected to have a cash runway through Phase 2b […]
Read MoreJanuary 18, 2023
National Institute on Aging (NIA) awards $21M grant to support key phase 2b study of EIP Pharma’s neflamapimod in dementia with Lewy bodies
BOSTON, MA, January 18th, 2022 /PRNewswire/ – EIP Pharma Inc., a clinical stage company focused on developing treatments for neurodegenerative diseases today announced that the National Institute on Aging (NIA) of the National Institutes of Health (NIH) awarded the Company a grant of $21 million to support a 160-patient phase 2b study of neflamapimod in […]
Read MoreView All News
Presentations
November 4, 2024
CTAD – LB25 – Plasma biomarker data indicates clinical activity of neflamapimod in dementia with Lewy bodies (DLB) is mediated through effects on the basal forebrain cholinergic system
Read More
July 29, 2024
Poster #91713: Neflamapimod treatment reduces plasma glial fibrillary acidic protein GFAP levels in patients with dementia with Lewy bodies (DLB) who do not have co-existing AD co-pathology
Read More
April 27, 2023
Presentation at AD/PD™ 2023 Conference on MRI Effects of Neflamapimod on the Basal Forebrain
Read More
View All Presentations
Corporate Presentation
Click below to download a PDF copy of EIP Pharma’s latest corporate presentation.
Download